摘要： 抗血小板药物目前仍是缺血性卒中急性期治疗和二级预防的常规用药。经典抗血小板药物阿司匹林、氯吡格雷的临床疗效已经肯定，但仍存在一些不足，如药物耐受性、增加出血风险等。因此，新型抗血小板药物以其不同的药代动力学和药效学特性与经典抗血小板药物互补，并能克服其临床应用的局限性而受到关注并逐渐在临床推广应用。本文拟对已发表的新型抗血小板药物的临床研究证据进行概述，并提出其临床应用所面临的挑战。

关键词: 血小板聚集抑制剂, 脑缺血, 卒中, 综述

Abstract: Nowadays, antiplatelet drugs are still the routine medication in the acute phase and in secondary prevention of ischemic stroke. Although the clinical effect of classic antiplatelet drugs, such as aspirin and clopidogrel, has been recognized, some problems still exist, such as clopidogrel resistance and increased bleeding risk. Therefore, new antiplatelet drugs have been studied and are incorporated into the clinical use currently. Their different pharmacokinetic and pharmacodynamic properties are good additions to the classic antiplatelet therapy, so as to overcome the limitations of the latter. This article will summarize existing clinical evidences and highlight the main features of new antiplatelet drugs, as well as listing some challenges in the use of these therapies.

Key words: Platelet aggregation inhibitors, Brain ischemia, Stroke, Review